US5470832A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibitors of geranylgeranyl-protein transferase
Assignee: Merck and Co Inc
•
Filing: 1994-01-31
•
Granted: 1995-11-28
•
Expires: 2014-01-31
Abstract
Abstract The compounds disclosed am analogs of the CAAX motif of proteins that can be modified by geranylgeranylation in vivo that selectively inhibit the geranylgeranylation of several proteins. The relatively poor activity of the compounds against the farnesyl protein transferase, which modifies several proteins important in cellular replication, allows the use of the compounds of the instant invention to treat diseases which which am regulated by the function of a geranylgeranylated protein, such as certain cancers and inflammatory diseases. Further contained in this invention are chemotherapeutic compositions containing these geranylgeranyl protein transfcrase type I inhibitors and methods for their production.
Inventors
- 👤 Jackson B. Gibbs
- 👤 Samuel L. Graham
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 07:17
CPC Classifications
C; C07; C07C; C07C323/00; C07C323/23; C07C323/24; C07C323/25; A; A61; A61P; A61P29/00; A61P35/00; A61P43/00; C07K; C07K5/00; C07K5/04; C07K5/08; C07K5/0802; C07K5/0804; C07K5/0808; A61K; A61K38/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
131 words
A compound which inhibits geranylgeranyl protein transferase type I, and is a selectively more potent inhibitor of geranylgeranyl protein transferase than of farnesyl protein transferase, having the formula I: ##STR12## wherein: R 1 and R 2 are independently selected from: a) C 2 -C 8 alkyl; b) C 2 -C 8 alkenyl; c) C 2 -C 8 alkynyl; d) substituted C 1 -C 8 alkyl; e) aryl; f) substituted aryl; g) heteroaryl; h) substituted heteroaryl; and i) the side chain of a naturally occurring amino acid; R 3 is selected from alkyl, alkenyl and alkynyl of 1 to 6 carbon atoms, either branched or straight chain, which is unsubstituted or substituted with a phenyl group; X--Y is ##STR13## and Z is H 2 or O; or the pharmaceutically acceptable: salts thereof.
Claim 2
Dependent Claim
131 words
A compound which inhibits geranylgeranyl protein transferase type I, and is a selectively more potent inhibitor of geranylgeranyl protein transferase than of farnesyl protein transferase, having the formula I: ##STR12## wherein: R 1 and R 2 are independently selected from: a) C 2 -C 8 alkyl; b) C 2 -C 8 alkenyl; c) C 2 -C 8 alkynyl; d) substituted C 1 -C 8 alkyl; e) aryl; f) substituted aryl; g) heteroaryl; h) substituted heteroaryl; and i) the side chain of a naturally occurring amino acid; R 3 is selected from alkyl, alkenyl and alkynyl of 1 to 6 carbon atoms, either branched or straight chain, which is unsubstituted or substituted with a phenyl group; X--Y is ##STR13## and Z is H 2 or O; or the pharmaceutically acceptable: salts thereof.
Claim 3
Dependent Claim
154 words
A prodrug of a compound of claim 1 having the formula II: ##STR14## wherein: R 1 and R 2 are independently selected from: a) C 2 -C 8 alkyl; b) C 2 -C 8 alkenyl; c) C 2 -C 8 alkynyl; d) substituted C 1 -C 8 alkyl; e) aryl; f) substituted aryl; g) heteroaryl; h) substituted heteroaryl; and i) the side chain of a naturally occurring amino acid; R 3 is selected from alkyl, alkenyl and alkynyl of 1 to 6 atoms either branched or straight chain which is unsubstituted or substituted with a phenyl group; X--Y is ##STR15## R 4 is selected from: a) C 1 -C 8 alkyl; b) C 3 -C 8 alkenyl; c) C 3 -C 8 alkynyl; d) substituted C 1 -C 8 alkyl; e) aryl; f) substituted aryl; g) heteroaryl; and h) substituted heteroaryl; and Z is H 2 or O; or a pharmaceutically :acceptable salt thereof.
Claim 4
Dependent Claim
30 words
A compound which inhibits geranylgeranyl-protein transferase type I which is: N-(2(R)-amino-3-mercaptopropyl)-valyl-isoleucyl-leucine; N-(2(R)-amino-3-mercaptopropyl)-valyl-isoleucyl-leucine methyl ester; N-[5(S)-(2(R)-amino-3-mercaptopropylamino)-6(S)-methyl-2-(R)-isopropyl-3,4(E)-heptenoyl]-leucine; N-[5 (S)-(2(R)-amino-3 -mercaptopropylamino)-6(S)-methyl-2(R)-isopropyl-3,4(E)-heptenoyl]-leucine methyl ester; N-[2(S)-(2(S)-(2(R)-animo-3-mercaptopropylamino)-3(S)-methylpentyloxy)-3-methylbutanoyl]-leucine; N-[2(S)-(2(S)-(2(R)-amino-3-mercaptopropylamino)-3(S)-methylpentyloxy)-3-methylbutanoyl]-leucine methyl ester; or the pharmaceutically acceptable salts thereof.
Claim 5
Dependent Claim
30 words
A compound which inhibits geranylgeranyl-protein transferase type I which is: N-(2(R)-amino-3-mercaptopropyl)-valyl-isoleucyl-leucine; N-(2(R)-amino-3-mercaptopropyl)-valyl-isoleucyl-leucine methyl ester; N-[5(S)-(2(R)-amino-3-mercaptopropylamino)-6(S)-methyl-2-(R)-isopropyl-3,4(E)-heptenoyl]-leucine; N-[5 (S)-(2(R)-amino-3 -mercaptopropylamino)-6(S)-methyl-2(R)-isopropyl-3,4(E)-heptenoyl]-leucine methyl ester; N-[2(S)-(2(S)-(2(R)-animo-3-mercaptopropylamino)-3(S)-methylpentyloxy)-3-methylbutanoyl]-leucine; N-[2(S)-(2(S)-(2(R)-amino-3-mercaptopropylamino)-3(S)-methylpentyloxy)-3-methylbutanoyl]-leucine methyl ester; or the pharmaceutically acceptable salts thereof.
Claim 6
Dependent Claim
16 words
The compound according to claim 1 which is: N-(2(R)-amino-3-mercaptopropyl)-valyl-isoleucyl-leucine; ##STR16## or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
27 words
A prodrug of a compound which inhibits geranylgeranyl-protein transferase type I according to claim 2 which is: N-(2(R)-amino-3-mercaptopropyl)-valyl-isoleucyl-leucine methyl ester; ##STR17## or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
19 words
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
19 words
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
38 words
A method of inhibiting the geranylgeranylation of proteins by geranylgentnyl protein transferase type I in a patient in need of such inhibition which comprises administering to the patient a pharmaceutically effective amount of the composition of claim 6.
Claim 11
Dependent Claim
31 words
A method of treating an inflammatory disease in a patient in need of such treatment which comprises administering to the patient a pharmaceutically effective amount of the composition of claim 6.
Claim 12
Dependent Claim
31 words
A method of treating an inflammatory disease in a patient in need of such treatment which comprises administering to the patient a pharmaceutically effective amount of the composition of claim 7.
References Cited (Backward Citations)
EP0535731A2
Cited
US5238922A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-11-27 | 1999-05-29 | 1999-11-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-11-27 | 2003-05-29 | 2003-11-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-11-27 | 2007-05-29 | 2007-11-28 | $7700.00 | Window Closed / Lapsed |